This trial has been completed.

Condition attention deficit hyperactivity disorder
Treatments text- messaging, treatment as usual
Sponsor Massachusetts General Hospital
Collaborator American Academy of Child Adolescent Psychiatry.
Start date January 2014
End date August 2016
Trial size 35 participants
Trial identifier NCT01967485, 2013-P-002161


The purpose of this study is to determine if an individualized text messaging intervention for the parents of children with Attention Deficit/Hyperactivity Disorder is effective in improving medication adherence and disease management.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Primary purpose health services research
Masking no masking
Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
text- messaging
Text messages will be sent to the parents of children enrolled in the study.
treatment as usual
Children will receive stimulant treatment for ADHD.
(Active Comparator)
Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
treatment as usual
Children will receive stimulant treatment for ADHD.

Primary Outcomes

Medication Adherence
time frame: Six Months

Eligibility Criteria

All participants from 6 years up to 17 years old.

Inclusion Criteria: - Male or female children ages 6-17 years - A diagnosis of ADHD (inattentive, hyperactive/impulsive, or combined type) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) based on clinical assessment and supported by a Clinical Global Impression- ADHD (CGI-ADHD) Severity Score of at least 4 (Moderately Ill) - Has a parent in possession of a cellular phone with text messaging capabilities and is interested in and willing to receive planned text messages - Has never been treated with stimulant medication, or has begun treatment with stimulant medication within three months of study enrollment. Exclusion Criteria: - Any serious, unstable, chronic medical condition, per clinician assessment - Cardiovascular disease - Current or past history of seizures - Treatment with stimulant medication beyond three months prior to enrollment - Pregnant or nursing females - Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild - Unstable psychiatric illness other than ADHD, including, but not limited to: Autism, Bipolar Disorder, Psychosis, Major Depressive Disorder, Anorexia, Bulimia, Post-Traumatic Stress Disorder and Anxiety Disorders - History of multiple adverse drug reactions - Presence of suicidal risk, or homicidality - Unwilling/unable to comply with study procedures - Poor command of the English language

Additional Information

Official title Text Messaging Adherence to Stimulant Medication
Principal investigator Mai Uchida, MD
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Massachusetts General Hospital.